Novo India Slashes Norditropin FlexPro Prices by 35% to Boost Access
Novo India reduces prices of Norditropin FlexPro by up to 35% to make growth hormone therapy more affordable for children and adults.
In a major move to make essential healthcare more accessible, Novo India has announced a significant price reduction of up to 35% for Norditropin FlexPro. This innovative growth hormone therapy, used by adults and children battling growth hormone deficiency, is now available under a new India-specific pricing structure to ease the financial burden on families.
Significant Price Drops Across Dose Strengths
The price revision, which comes into effect immediately, applies to two different dose strengths of the therapy. The cost reductions are as follows:
- 10 mg Device: The price has been slashed by 33%, dropping from ₹16,836 to ₹11,300, resulting in a saving of ₹5,539 per pen.
- 15 mg Device: The price has been reduced by 35%, falling from ₹25,254 to ₹16,450, offering a saving of ₹8,802 per pen.
Addressing a Rare Endocrine Disorder
Growth hormone deficiency is a rare condition that occurs when the pituitary gland fails to produce sufficient hormones to support normal growth. This can be present from birth or develop later due to structural abnormalities, genetic factors, or damage to the pituitary region, though in many cases, the exact cause remains unknown.
Vikrant Shrotriya, Managing Director of Novo India, highlighted the rarity of the condition, noting that estimates suggest it affects approximately 1 in 4,000 to 1 in 10,000 children. He emphasized that this price reduction is a direct reflection of the company's commitment to ensuring that life-changing treatments reach children and families across the country.
Expert Insights on Diagnosis and Treatment
Medical professionals stress the importance of early detection. Dr. Saurabh Uppal, a Paediatric Endocrinologist at Govt Medical College Amritsar, advised parents not to assume a child will simply "catch up" if their growth is consistently slower than expected. Instead, he urges families to seek medical evaluations to identify if growth hormone deficiency is the cause.
Adding to this, Dr. Archna Dayal Arya, Senior Consultant at Sir Ganga Ram Hospital, New Delhi, pointed out that timely diagnosis and a personalized therapy plan are critical for the best possible outcomes. She noted that the delivery device provides a convenient and effective way for families to manage this rare disease.
Designed for Ease of Use
Norditropin FlexPro is not just about the medication but also the delivery. It is a pre-filled, user-friendly growth hormone pen specifically designed for children who require long-term therapy. The device aims to improve adherence and make the daily treatment routine less daunting for both the young patients and their caregivers.
Novo India has stated that it will continue to collaborate with healthcare providers and caregivers to ensure that world-class therapies for non-communicable diseases remain timely and affordable for the Indian population.